Recent market status and trends of fractionated plasma products

The global plasmas proteins market has continued to grow throughout the past decade, reaching over $21 billion in sales in 2016. Five trends have recently affected the sales of plasma proteins significantly, including: (I) immunoglobulin has increased its primacy as the plasma market driver; (II) rise of China’s plasma industry, both domestically and globally; (III) emergence and growth of several specialty products, including C1 esterase inhibitor (C1-INH), prothrombin complex concentrate (PCC) and alpha-1 antitrypsin (AAT); (IV) relative decline of the plasma-derived coagulation factors in favor of recombinant alternatives; and (V) growing role of the United States as the global supplier of source plasma. Due to these events, the industry has positively affected more patients as treatment has expanded in many areas around the globe.